Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. China Resources Jiangzhong Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 56.19%.
SHSE:600750's ROC (Joel Greenblatt) % is ranked better than 88.78% of 980
companies
in the Drug Manufacturers industry
Industry Median: 11.695
vs SHSE:600750: 65.38
China Resources Jiangzhong Pharmaceutical Co (SHSE:600750) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Jiangzhong Pharmaceutical Co ROC (Joel Greenblatt) % Chart
China Resources Jiangzhong Pharmaceutical Co Annual Data
SHSE:600750 vs ZTS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Jiangzhong Pharmaceutical Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Jiangzhong Pharmaceutical Co ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
China Resources Jiangzhong Pharmaceutical Co ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 56.19% mean?
China Resources Jiangzhong Pharmaceutical Co (SHSE:600750) has a ROC (Joel Greenblatt) % of 56.19% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on China Resources Jiangzhong Pharmaceutical Co and its competitors. This is near median its historical median of 57.87. Over the past decade, China Resources Jiangzhong Pharmaceutical Co's ROC (Joel Greenblatt) % has ranged from 51.76 to 65.38. According to the industry distribution chart, China Resources Jiangzhong Pharmaceutical Co ranks #110 out of 980 companies in the Drug Manufacturers industry, placing it in the top 11.2%.
Is China Resources Jiangzhong Pharmaceutical Co's ROC (Joel Greenblatt) % too high?
China Resources Jiangzhong Pharmaceutical Co's current ROC (Joel Greenblatt) % of 56.19% is near median its 10-year median of 57.87. Over the past 10 years, this metric has ranged from a low of 51.76 to a high of 65.38. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.70. China Resources Jiangzhong Pharmaceutical Co's value of 56.19% is 380.5% above this industry median. Based on the distribution chart, China Resources Jiangzhong Pharmaceutical Co ranks #110 out of 980 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China Resources Jiangzhong Pharmaceutical Co has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does China Resources Jiangzhong Pharmaceutical Co's ROC (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China Resources Jiangzhong Pharmaceutical Co ranks #110 out of 980 companies for ROC (Joel Greenblatt) %. This places China Resources Jiangzhong Pharmaceutical Co in the top 11% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.70. China Resources Jiangzhong Pharmaceutical Co's value of 56.19% is 380.5% above this benchmark. Historically, China Resources Jiangzhong Pharmaceutical Co's own ROC (Joel Greenblatt) % has ranged from 51.76 to 65.38 over the past decade. While the company's 10-year median is 57.87 vs. the industry median of 11.70, China Resources Jiangzhong Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.70, based on 980 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Jiangzhong Pharmaceutical Co's current ROC (Joel Greenblatt) % of 56.19% is 380.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on China Resources Jiangzhong Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Jiangzhong Pharmaceutical Co's current ROC (Joel Greenblatt) % is 56.19%, which is near median its own 10-year median of 57.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Jiangzhong Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, China Resources Jiangzhong Pharmaceutical Co (SHSE:600750) is currently considered Fairly Valued. The stock's GF Value™ is ¥21.53, compared to a current price of ¥22.52 — trading 4.6% above its estimated fair value. The current ROC (Joel Greenblatt) % is 56.19%, which is near median its 10-year median of 57.87 and 380.5% above the Drug Manufacturers industry median of 11.70. China Resources Jiangzhong Pharmaceutical Co's overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For China Resources Jiangzhong Pharmaceutical Co (SHSE:600750), the current ROC (Joel Greenblatt) % is 56.19% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Jiangzhong Pharmaceutical Co (SHSE:600750) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Jiangzhong Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥22.52 is trading 4.6% above its estimated GF Value™ of ¥21.53.
GuruFocus considers China Resources Jiangzhong Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:600750:
ROC (Joel Greenblatt) %: 56.19% (near median its 10-year median of 57.87)
GF Value™: ¥21.53 vs. price of ¥22.52 (4.6% above fair value)
Industry Position: 380.5% above the Drug Manufacturers median (#110 of 980)
No single metric tells the full story. See the SHSE:600750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Jiangzhong Pharmaceutical Co Ltd is engaged in the research and development, production, and sale of over-the-counter pharmaceuticals and health-related products, including functional foods. Its business activities also include the production and sale of proprietary Chinese medicines and chemical drugs.
88GF Score
Get the complete analysis for SHSE:600750
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600750 has been successfully added to your 
